![logo](/logos/FDMT.webp)
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
15.07 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | 4D Molecular Therapeutics, Inc. |
Symbool | FDMT |
Munteenheid | USD |
Prijs | 15.07 |
Beurswaarde | 783,181,872 |
Dividendpercentage | 0% |
52-weken bereik | 9.44 - 36.25 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. David H. Kirn M.D. |
Website | https://www.4dmoleculartherapeutics.com |
An error occurred while fetching data.
Over 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)